PTGX
Price
$85.13
Change
+$0.74 (+0.88%)
Updated
Nov 19 closing price
Capitalization
5.32B
118 days until earnings call
Intraday BUY SELL Signals
QNRX
Price
$18.18
Change
-$1.06 (-5.51%)
Updated
Nov 19 closing price
Capitalization
15.29M
Intraday BUY SELL Signals
Interact to see
Advertisement

PTGX vs QNRX

Header iconPTGX vs QNRX Comparison
Open Charts PTGX vs QNRXBanner chart's image
Protagonist Therapeutics
Price$85.13
Change+$0.74 (+0.88%)
Volume$989.45K
Capitalization5.32B
Quoin Pharmaceuticals
Price$18.18
Change-$1.06 (-5.51%)
Volume$130.47K
Capitalization15.29M
PTGX vs QNRX Comparison Chart in %
PTGX
Daily Signal:
Gain/Loss:
QNRX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
PTGX vs. QNRX commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a Hold and QNRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (PTGX: $85.11 vs. QNRX: $18.22)
Brand notoriety: PTGX and QNRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTGX: 79% vs. QNRX: 16%
Market capitalization -- PTGX: $5.32B vs. QNRX: $15.29M
PTGX [@Biotechnology] is valued at $5.32B. QNRX’s [@Biotechnology] market capitalization is $15.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTGX’s FA Score shows that 2 FA rating(s) are green whileQNRX’s FA Score has 2 green FA rating(s).

  • PTGX’s FA Score: 2 green, 3 red.
  • QNRX’s FA Score: 2 green, 3 red.
According to our system of comparison, PTGX is a better buy in the long-term than QNRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTGX’s TA Score shows that 4 TA indicator(s) are bullish while QNRX’s TA Score has 6 bullish TA indicator(s).

  • PTGX’s TA Score: 4 bullish, 4 bearish.
  • QNRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, QNRX is a better buy in the short-term than PTGX.

Price Growth

PTGX (@Biotechnology) experienced а +0.31% price change this week, while QNRX (@Biotechnology) price change was +50.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

PTGX is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($5.32B) has a higher market cap than QNRX($15.3M). PTGX has higher P/E ratio than QNRX: PTGX (128.95) vs QNRX (0.01). PTGX YTD gains are higher at: 120.492 vs. QNRX (-19.998). PTGX has higher annual earnings (EBITDA): 26.8M vs. QNRX (-12.58M). PTGX has more cash in the bank: 570M vs. QNRX (7.79M). QNRX has less debt than PTGX: QNRX (6.21M) vs PTGX (11.3M). PTGX has higher revenues than QNRX: PTGX (209M) vs QNRX (0).
PTGXQNRXPTGX / QNRX
Capitalization5.32B15.3M34,778%
EBITDA26.8M-12.58M-213%
Gain YTD120.492-19.998-603%
P/E Ratio128.950.011,074,979%
Revenue209M0-
Total Cash570M7.79M7,317%
Total Debt11.3M6.21M182%
FUNDAMENTALS RATINGS
PTGX vs QNRX: Fundamental Ratings
PTGX
QNRX
OUTLOOK RATING
1..100
1833
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
31100
SMR RATING
1..100
61100
PRICE GROWTH RATING
1..100
3735
P/E GROWTH RATING
1..100
210
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QNRX's Valuation (24) in the Biotechnology industry is significantly better than the same rating for PTGX (91). This means that QNRX’s stock grew significantly faster than PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (31) in the Biotechnology industry is significantly better than the same rating for QNRX (100). This means that PTGX’s stock grew significantly faster than QNRX’s over the last 12 months.

PTGX's SMR Rating (61) in the Biotechnology industry is somewhat better than the same rating for QNRX (100). This means that PTGX’s stock grew somewhat faster than QNRX’s over the last 12 months.

QNRX's Price Growth Rating (35) in the Biotechnology industry is in the same range as PTGX (37). This means that QNRX’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's P/E Growth Rating (2) in the Biotechnology industry is in the same range as QNRX (10). This means that PTGX’s stock grew similarly to QNRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTGXQNRX
RSI
ODDS (%)
Bearish Trend 1 day ago
60%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 3 days ago
88%
Declines
ODDS (%)
Bearish Trend 8 days ago
76%
Bearish Trend 15 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
60%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
PTGX
Daily Signal:
Gain/Loss:
QNRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRM26.050.33
+1.28%
Perimeter Solutions Inc
BBDO3.130.02
+0.64%
Banco Bradesco SA
OVBC35.30-0.26
-0.73%
Ohio Valley Banc Corp
ACEL9.61-0.18
-1.84%
Accel Entertainment
KAPA0.71-0.04
-4.83%
Kairos Pharma Ltd.

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been closely correlated with BIESF. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if PTGX jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+0.85%
BIESF - PTGX
66%
Closely correlated
N/A
DNLI - PTGX
41%
Loosely correlated
-3.20%
ORMP - PTGX
37%
Loosely correlated
+0.80%
MLYS - PTGX
37%
Loosely correlated
-2.93%
TRVI - PTGX
37%
Loosely correlated
-2.30%
More

QNRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, QNRX has been loosely correlated with NEVPF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if QNRX jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QNRX
1D Price
Change %
QNRX100%
-5.30%
NEVPF - QNRX
38%
Loosely correlated
N/A
ATNM - QNRX
35%
Loosely correlated
-4.90%
PRQR - QNRX
32%
Poorly correlated
-2.64%
WVE - QNRX
32%
Poorly correlated
-3.23%
PTGX - QNRX
31%
Poorly correlated
+0.85%
More